EGR3 and cancer: Kwon et al. have demonstrated that EGR3 can bind to the promoter sequences of HDAC6, resulting in the altered expression of interleukin-27 (IL-27), and the EGR3-HDAC6-IL-27 axis is necessary for enhancing the tumorigenic potential of cancer cells in the context of allergic inflammation by mediating cellular interactions [31].